CTLA4 and non-small cell lung carcinoma: In recent years, research on immune checkpoint inhibitors of PD-1, PD-L1, and CTLA-4 have become a hot topic in the field of cancer because of their remarkable efficacy in prolongation of the survival of patients with non-small cell lung cancer, melanoma, and renal cell carcinoma [21, 22].